Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Upstream Bio (Nasdaq: UPB), a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in an upcoming investor event.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB), a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in an upcoming investor event. CEO Rand Sutherland, MD will engage in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET.
The presentation will be accessible via live webcast in the Events section of the company's investor relations website, with a replay available after the event.
Details
News Market Reaction – UPB
On Sep 9, the day this news came out, UPB closed 2.62% below the previous close.
Data tracked by StockTitan Argus for the Sep 9 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET.
A live webcast of the fireside chat will be available under the Events tab on the Investors section of the Company’s website. A replay will be posted on the Company's website following the presentation.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.